Brand name pharmaceutical companies’ concerns about profit losses related to the UNITAID patent pool might undermine access to newer and appropriate HIV medicine formulations in resource-limited settings. A universally agreed strategy to supplement UNITAID plan is therefore needed, writes Daniele Dionisio.